Subscribe for relevant insights delivered straight to your inbox
How the coronavirus pandemic is shining a spotlight on the long-term potential of health care’s advanced research and technology.
As the coronavirus spreads, some health care companies have warned about falling revenues, while other firms are working on a treatment – and seeing their stocks rise.
Portfolio Manager John Lloyd offers his views on how potential outcomes of the U.S. presidential election could impact corporate bond markets.
After a volatile 2019, what can health care investors expect in the new year?
Amid a raft of costly proposals to overhaul U.S. health care, companies are hustling to find efficiencies and improve patient outcomes.
Portfolio Manager Andy Acker discusses biotechnology’s sell-off this year and why he thinks investors should not give up on the sector.
At Janus Henderson, we believe in the sharing of expert insight for better investment and business decisions.
We call this ethos Knowledge. Shared
There’s more than one way to gain exposure to advances in oncology, say Andy Acker, Dan Lyons and Luyi Guo of the Global Life Sciences Team.
After hitting roadblocks last week, the effort to lower drug prices in the U.S. is changing course, with implications for investors.
Focusing on secular growth drivers as the technology and health care sectors experience rapid change – and bouts of volatility.
Subscribe for relevant insights delivered straight to your inbox
